ライフサイエンスコーパス: percutaneous transluminal angioplasty

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 oons in patients undergoing femoro-popliteal percutaneous transluminal angioplasty.

2 was smaller in the medical group versus the percutaneous transluminal angioplasty and stenting (PTAS

3 roke that is increasingly being treated with percutaneous transluminal angioplasty and stenting (PTAS

4 RECENT FINDINGS: Percutaneous transluminal angioplasty and stenting is a

5 and D lesions are not randomized and receive percutaneous transluminal angioplasty and stenting or fe

6 to receive either femoropopliteal bypass or percutaneous transluminal angioplasty and stenting; pati

7 Contemporary studies of the use of percutaneous transluminal angioplasty as primary treatme

8 Two balloon (percutaneous transluminal angioplasty) catheters were us

9 porary studies (2005-2015) on the effects of percutaneous transluminal angioplasty for the treatment

10 Contemporary outcomes of percutaneous transluminal angioplasty for the treatment

11 At many institutions, percutaneous transluminal angioplasty has become the tre

12 Peripheral percutaneous transluminal angioplasty is fraught with a

13 treatment of peripheral artery disease with percutaneous transluminal angioplasty is limited by the

14 ctory angina pectoris when bypass surgery or percutaneous transluminal angioplasty is not indicated.

15 oved the likelihood of technical success for percutaneous transluminal angioplasty of dialysis access

16 and publication bias were observed for most percutaneous transluminal angioplasty outcomes.

17 f patients with critical limb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out

18 l restenosis and reintervention rates versus percutaneous transluminal angioplasty (PTA) and improve

19 The RCT compared the DES with percutaneous transluminal angioplasty (PTA) and provisio

20 treatment with a low-dose DCB or an uncoated percutaneous transluminal angioplasty (PTA) balloon.

21 dy of mature accesses that underwent balloon percutaneous transluminal angioplasty (PTA) between Janu

22 el drug-eluting balloons versus conventional percutaneous transluminal angioplasty (PTA) for the redu

23 We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the trea

24 eserved for lesions that are not amenable to percutaneous transluminal angioplasty (PTA) or for recur

25 runs were higher (all P<.001) than those for percutaneous transluminal angioplasty (PTA), as were rad

26 e 1-year outcomes compared with conventional percutaneous transluminal angioplasty (PTA), yet durabil

27 t has improved the patency rate of SFA after percutaneous transluminal angioplasty (PTA).

28 eal changes in renal function at the time of percutaneous transluminal angioplasty (PTA).

29 gned to DCB (n=200) or standard angioplasty (percutaneous transluminal angioplasty [PTA]) (n=100).

30 Alleviating vascular restenosis after percutaneous transluminal angioplasty remains a formidab

31 (2 with subclavian-carotid bypass and 5 with percutaneous transluminal angioplasty stenting of the su

32 , and reinterventions after femoro-popliteal percutaneous transluminal angioplasty up to 1 year of fo

33 o has successfully undergone angiography and percutaneous transluminal angioplasty using CO2 as the s

34 Percutaneous transluminal angioplasty was then performed

35 popliteal atherosclerotic disease undergoing percutaneous transluminal angioplasty were randomized to

36 c femoropopliteal peripheral artery disease, percutaneous transluminal angioplasty with a paclitaxel-

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。